成人国产在线视频,无限资源中文免费,无限视频资源免费观看视频,47147大但人文艺术欣赏

Inaticabtagene Autoleucel (CNCT19 Injection) is the first core product candidate of Juventas Cell Therapy, it is also the first CD19-directde CAR-T product with Chinese independent intellectual property rights. CD19 scFv (HI19a) structure and CMC technique. It has obtained three IND approval from the National Medical Products Administration (NMPA), for the treatment of adult relapsed and refractory acute lymphoblastic leukemia, relapsed and refractory aggressive B-cell non-Hodgkin lymphoma, and pediatric and adolescent B-cell acute lymphoblastic leukemia. In addition, it was granted Breakthrough Therapy Designation by Center for Drug Evaluation, National Medical Products Administration (CDE, NMPA) and Orphan Drug Designation (ODD) by the U.S. FDA. NMPA has given the acceptance of the New Drug Application (NDA) of Inaticabtagene Autoleucel (CNCT19 Injection) for the treatment of adult relapsed and refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

• 2023-03-09
  Juventas Announces FDA Clearance of the IND Application for Clinical Trial of Inaticabtagene Autoleucel
• 2022-12-22
  Juventas’ Inaticabtagene Autoleucel (CNCT19 Injection) Granted Priority Review by CDE, NMPA
• 2022-12-13
  NMPA of China has accepted the NDA of Inaticabtagene Autoleucel (CNCT19 Injection) for the treatment of adult relapsed and refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

Clinical development abilities and scalable pipeline layout demonstrate the vitality of an excellent biomedical company. Juventas develops by technological innovation covering blood and solid tumors to meet clinical demands and accelerate industrialization.